Figure 2From: Impact of treatment with bevacizumab beyond disease progression: a randomized phase II study of docetaxel with or without bevacizumab after platinum-based chemotherapy plus bevacizumab in patients with advanced nonsquamous non–small cell lung cancer (WJOG 5910L) Disease course patterns for first-line chemotherapy. Red arrows indicate discontinuation of first-line treatment because of PD; broken black arrows indicate discontinuation before PD.Back to article page